Steven Ionov
TD Cowen, Research Division
All right. Good afternoon, everyone, and thank you once again for coming to the 46th Annual TD Cowen Healthcare Conference. I’m Steven Ionov on the biotech team, and I’m joined by the management of Alector Inc. We’ll be hearing a presentation first from Eric Brown, the Head of Antibody Discovery and Protein Engineering, and then we may take some questions. So Eric, thank you for coming. Take it away.
Eric Brown
So in addition to my role leading antibody discovery and protein engineering, I’ve also been heading up our ABC platform for the last 7 or so years, and that will be the primary focus of our talk today. So if you look at our — if you look at our portfolio here at Alector, we do have one non-ABC-enabled program, AL101, which has an interim futility analysis in the first half of this year conducted by an independent monitoring committee.
I will not be talking about that particular program today because the focus is entirely on our ABC platform, but I will be talking about the rest of these programs, including our lead antibody candidate, an Aß antibody enabled by ABC, our lead enzyme candidate, which is a GCase enzyme. Both of these programs are headed towards IND.
And then I’ll introduce our siRNA platform, which is also being enabled by the blood-brain barrier technology as exemplified by our TAU ABC molecule and then there are a couple of other lead molecules or follow-on molecules that I will identify in our siRNA platform.
So to
